Experimental study of evodiamine on reversing multidrug resistance of K562/Adr cells / 中草药

ABSTRACT

Objective: To study the effect of evodiamine (EVO) on the proliferation, cell cycle, and multidrug resistance (MDR) of leukemia K562 and K562/Adr cells. Methods: The effect on the proliferation was detected by CCK-8 kit and/or daunorubicin (DNR). The resistance index (RI) and reversal fold (RF) were calculated. The effect of EVO on cell cycle was tested by flow cytometry; Flow cytometry was used to check the fluorescence intensity of DNR. The expression of MDR1 gene in leukemia K562 and K562/Adr cells was detected by q-PCR. The expression of MDR1 and BCRP proteins in leukemia K562 and K562/Adr cells were detected by Western blotting. Results: CCK-8 test results showed that the proliferation of K562 and K562/Adr cells induced by EVO and DNR was inhibited in a dose and time dependent manner. The RI of DNR on K562/Adr cells was 30.54, the RI of EVO on K562/Adr cells was 19.09|, compared with K562 cells; The RF of DNR + EVO on K562/Adr cells was 12.07.The expression of BCRP and MDR1 protein of K562/Adr cells was significantly decreased in K562/Adr cells induced by EVO and DNR. Conclusion: Therefore EVO can effectively reverse the DNR resistance in K562/Adr cells, which may be related to reduce the expression of MDR1 on cell membrane.